Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases.
Elsa L S A van LiereAhmed B BayoumyChris J J MulderBen WarnerBu HayeeBilal A MateenJonathan D NolanNanne K H de BoerSimon H C AndersonAzhar R AnsariPublished in: Digestive diseases and sciences (2021)
Our poor AZAm outcomes emphasize that optimization of azathioprine is needed. We demonstrated a long-term safe and more effective profile of first-line LDAA. This co-therapy may therefore be considered standard first-line immunosuppressive.